Boosting natural TNF inhibitors in the human body

MYMD-1® regulates the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines, including TNF-α, IL-6 and IL-17A.


MYMD-1® targets the root causes of inflammation. It is not detrimental to cell viability and is a small molecule that can cross the blood-brain barrier, potentially enabling it to treat brain-related disease.


MYMD-1® is being developed to target aging (sarcopenia) and depression in age or inflammatory-related diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic.


The ease of oral dosing makes MYMD-1® more convenient than other drug treatments. In addition, MYMD is not immunosuppressive and has not been shown to cause serious side effects common with traditional therapies that treat inflammation.

Our immunotherapy research

MYMD-1® is an immunometabolic regulator, designed to regulate the release of inflammatory cytokines.

As a clinical-stage, synthetic plant alkaloid, MYMD-1® joins a class of more than 12,000 heterocyclic compounds, some of which have therapeutic properties. The mechanism of action and efficacy of MYMD-1® in diseases such as Multiple Sclerosis (MS), thyroiditis, and aging mouse models has been studied through collaboration with academic institutions with findings published in peer reviewed journals. 


We’re meeting demand for new treatments

The rising prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are driving demand for TNF inhibitors, like MYMD-1®. Studies show that 20% of the global population is suffering from chronic pain and estimate that the number of people suffering from rheumatoid arthritis alone might rise to over 78 million by 2040. (Data published by Research and Markets, March 16, 2018).

View MyMD Thought Leadership and News
  • This field is for validation purposes and should be left unchanged.